From: Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone
Altered expression of β-tubulin isotypes [41, 42]
Overexpression of the βIII-tubulin subunit [40, 43]
β-Tubulin mutations affecting microtubule stability and the binding of microtubule inhibitors [44–46]
Changes in microtubule-associated proteins (for example, tau and microtubule-associated protein-4) [47, 48]
Post-translational modifications of tubulin (for example, acetylation) [40]